Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2005 Mar 3:5:2.
doi: 10.1186/1472-6904-5-2.

Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women

Affiliations
Randomized Controlled Trial

Pharmacokinetics of isoflavones, daidzein and genistein, after ingestion of soy beverage compared with soy extract capsules in postmenopausal Thai women

Ekasin Anupongsanugool et al. BMC Clin Pharmacol. .

Abstract

Background: Isoflavones from soybeans may provide some beneficial impacts on postmenopausal health. The purpose of this study was to compare the pharmacokinetics and bioavailability of plasma isoflavones (daidzein and genistein) after a single dose of orally administered soy beverage and soy extract capsules in postmenopausal Thai women.

Methods: We conducted a randomized two-phase crossover pharmacokinetic study in 12 postmenopausal Thai women. In the first phase, each subject randomly received either 2 soy extract capsules (containing daidzin : genistin = 7.79 : 22.57 mg), or soy beverage prepared from 15 g of soy flour (containing daidzin : genistin = 9.27 : 10.51 mg). In the second phase, the subjects received an alternative preparation in the same manner after a washout period of at least 1 week. Blood samples were collected immediately before and at 0.5, 1, 2, 4, 6, 8, 10, 12, 24 and 32 h after administration of the soy preparation in each phase. Plasma daidzein and genistein concentrations were determined by using high performance liquid chromatography (HPLC). The pharmacokinetic parameters of daidzein and genistein, i.e. maximal plasma concentration (Cmax), time to maximal plasma concentration (Tmax), area under the plasma concentration-time curve (AUC) and half-life (t1/2), were estimated using the TopFit version 2.0 software with noncompartmental model analysis.

Results: There were no significant differences in the mean values of Cmax/dose, AUC0-32/dose, AUC0- proportional, variant/dose, Tmax, and t1/2 of genistein between both preparations. For pharmacokinetic parameters of daidzein, the mean values of Cmax/dose, Tmax, and t1/2 did not significantly differ between both preparations. Nonetheless, the mean AUC0-32/dose and AUC0- proportional, variant/dose after administration of soy extract capsules were slightly (but significantly, p < 0.05) higher than those of soy beverage.

Conclusion: The bioavailability of daidzein, which was adjusted for the administered dose (AUC/dose), following a single oral administration of soy beverage was slightly (but significantly) less than that of soy extract capsules, whereas, the bioavailability adjusted for administered dose of genistein from both soy preparations were comparable. The other pharmacokinetic parameters of daidzein and genistein, including Cmax adjusted for the dose, Tmax and t1/2, were not different between both soy preparations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of isoflavones.
Figure 2
Figure 2
Mean plasma daidzein concentration-time curves after a single dose of orally administered soy beverage and soy extract capsules.
Figure 3
Figure 3
Mean plasma genistein concentration-time curves after a single dose of orally administered soy beverage and soy extract capsules. (Note: the orally administered dose of genistein from soy extract capsules was approximately two times higher than that from soy beverage).

References

    1. Schneider HPG. Menopause: The state of the art in research and management. New York: The Parthenon Publishing; 2003.
    1. Women's Health Initiative Steering Committee Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701–12. doi: 10.1001/jama.291.14.1701. - DOI - PubMed
    1. Warren MP. A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol. 2004;190:1141–67. doi: 10.1016/j.ajog.2003.09.033. - DOI - PubMed
    1. Warren MP, Shortle B, Dominguez JE. Use of alternative therapies in menopause. Best Pract Res Clin Obstet Gynecol. 2002;16:411–48. doi: 10.1053/beog.2002.0290. - DOI - PubMed
    1. Song T, Barua K, Buseman G, Murphy PA. Soy isoflavone analysis: quality control and a new internal standard. Am J Clin Nutr. 1998;68:1474–1479. - PubMed

Publication types

LinkOut - more resources